Public Research Snapshot
Neuphoria Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates.
NEUP Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway
Neuphoria Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z
TickerNEUP
Market Cap9.8M
Cash RunwayUnknown
Next Catalystn/a
Pipeline
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| No public pipeline rows are loaded yet. | ||||
Catalyst Preview
No public catalyst rows matched this view yet.
Cash Runway Preview
Estimated cash runway: Unknown.
This is an automated estimate and may differ from company guidance.
Recent SEC Filings
- No public filing rows are loaded yet.
Clinical Trial Activity
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| No public trial rows are loaded yet. | ||||
Scientific Context
- clinical_stage | pivotal
- indication | men Best gift cards Best gifts for mom Best gifts for teens Best gifts for couple
- literature_publication | The Pathway to Proof-of-Concept for BNC210, a Negative Allosteric Modulator of the Alpha-7 Nicotinic Acetylcholine Receptor (nAChR), for Treatment of Psychiatric Disease.
- literature_publication | The Pathway to Proof-of-Concept for BNC210, a Negative Allosteric Modulator of the Alpha-7 Nicotinic Acetylcholine Receptor (nAChR), for Treatment of Psychiatric Disease.
- literature_publication | The Pathway to Proof-of-Concept for BNC210, a Negative Allosteric Modulator of the Alpha-7 Nicotinic Acetylcholine Receptor (nAChR), for Treatment of Psychiatric Disease.
Want the full NEUP research brief?
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.